Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00499668 |
RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.
PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.
Condition | Intervention |
---|---|
Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Nausea and Vomiting Unspecified Adult Solid Tumor, Protocol Specific |
Drug: aprepitant Drug: ondansetron hydrochloride |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized |
Official Title: | A Pilot Study of Aprepitant Versus Ondansetron for the Treatment of Opioid Induced Nausea and Vomiting |
Estimated Enrollment: | 60 |
Study Start Date: | August 2007 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
Patients complete the following questionnaires: Functional Assessment of Cancer Therapy-General (FACT-G); Center for Epidemiologic Studies Depression Scale (CES-D); and Brief Pain Index (BPI) at baseline and on day 7. Patients also complete symptom diaries documenting the following: number of episodes (an emetic episode is defined as a simple vomit or retch, or any number of continuous vomits or retches; distinct episodes that are separated by at least 1 minute) of vomiting or retching including the date and time; worst and average degree of nausea (recorded every 2 hours while awake during the first 24 hours after treatment and every 8 hours on days 1-7); and adverse events other than episodes of vomiting and nausea.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Nausea and vomiting (associated with opioid analgesic use) that is unrelieved by at least one standard antiemetic regimen (including 5HT3 antagonist and dexamethasone combination therapy)
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, Tennessee | |
Vanderbilt-Ingram Cancer Center | |
Nashville, Tennessee, United States, 37232-6838 |
Study Chair: | Barbara A. Murphy, MD | Vanderbilt-Ingram Cancer Center |
Study ID Numbers: | CDR0000558419, VU-VICC-SUPP-0513, VU-VICC-IRB-070193, MERCK-VU-VICC-SUPP-0513 |
Study First Received: | July 10, 2007 |
Last Updated: | October 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00499668 |
Health Authority: | United States: Federal Government |
unspecified adult solid tumor, protocol specific nausea and vomiting chronic myelogenous leukemia chronic eosinophilic leukemia chronic idiopathic myelofibrosis chronic neutrophilic leukemia essential thrombocythemia polycythemia vera adult acute lymphoblastic leukemia adult acute myeloid leukemia acute undifferentiated leukemia mast cell leukemia adult T-cell leukemia/lymphoma T-cell large granular lymphocyte leukemia chronic lymphocytic leukemia |
hairy cell leukemia prolymphocytic leukemia AIDS-related lymphoma adult Hodgkin lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma cutaneous B-cell non-Hodgkin lymphoma cutaneous T-cell non-Hodgkin lymphoma mycosis fungoides/Sezary syndrome adult grade III lymphomatoid granulomatosis adult nasal type extranodal NK/T-cell lymphoma Waldenstrom macroglobulinemia adult Burkitt lymphoma adult diffuse large cell lymphoma adult diffuse mixed cell lymphoma |
Sezary syndrome Chronic myelogenous leukemia Primary effusion lymphoma Hodgkin lymphoma, adult Lymphoma, small cleaved-cell, diffuse Lymphoma, large-cell, immunoblastic Lymphomatoid granulomatosis Preleukemia Leukemia, Prolymphocytic Hemorrhagic Disorders Hemorrhagic thrombocythemia Lymphoma, Large-Cell, Anaplastic Thrombocythemia, Hemorrhagic Aprepitant Myelodysplastic syndromes |
Essential thrombocytosis Precursor Cell Lymphoblastic Leukemia-Lymphoma Hematologic Diseases Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Leukemia, Myelomonocytic, Chronic Blood Coagulation Disorders Acute myelogenous leukemia Leukemia, Myeloid Serotonin Myelodysplastic myeloproliferative disease Waldenstrom Macroglobulinemia B-cell lymphomas Anaplastic large cell lymphoma Lymphoma, Non-Hodgkin Hairy cell leukemia |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Antiemetics Serotonin Antagonists Pathologic Processes Syndrome Therapeutic Uses Antipruritics Cardiovascular Diseases Dermatologic Agents Neoplasms by Histologic Type |
Disease Tranquilizing Agents Immune System Diseases Gastrointestinal Agents Central Nervous System Depressants Antipsychotic Agents Pharmacologic Actions Neoplasms Serotonin Agents Autonomic Agents Anti-Anxiety Agents Peripheral Nervous System Agents Central Nervous System Agents |